Education Center Search
Found Posts: 65
Search Publications
Reversal of Experimental Pulmonary Hypertension by PDGF Inhibition
This classic paper describes the experimental data from testing imatinib in animal models of pulmonary hypertension which justified Novartis to pursue its potential in PAH. The inclusion of data from human lungs of patients with PAH showing elevation of the expression of PDGF receptors make a compelling argument for the testing of imatinib in clinical trials.
Citation
Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005 Oct;115(10):2811-21.Source: https://pubmed.ncbi.nlm.nih.gov/16200212/
Right Heart Phenotype in Heart Failure with Preserved Ejection Fraction
High level review of right ventricular adaptation in HFpEF. These experts demonstrate the critical role of the RV in this setting and illustrate that pulmonary hypertension and RV failure represents an advanced stage of HFpEF.
Citation
Guazzi M, Naeije R. Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2021 Apr;14(4):e007840.Source: https://pubmed.ncbi.nlm.nih.gov/33866826/
The Overloaded Right Heart and Ventricular Interdependence
Comprehensive review of the relationship between the left and right ventricles in pulmonary hypertension. One cannot ignore that isolated pulmonary hypertension, even in the presence a normal left ventricle, is a biventricular disease. When there is coexisting left ventricular dysfunction the relationships become even more complex.
Citation
Naeije R, Badagliacca R. The overloaded right heart and ventricular interdependence. Cardiovasc Res. 2017 Oct 1;113(12):1474-1485.Source: https://pubmed.ncbi.nlm.nih.gov/28957537/
Sympathetic Nervous System Activation and Heart Failure: Current State of Evidence and the Pathophysiology in the Light of Novel Biomarkers
Sympathetic nervous system activation has been well established as a chronic maladaptive response to heart failure syndromes. This includes HFrEF, HFpEF, and right ventricular failure. Treatments that target the SNS are the basis for treating LV failure and improving survival. Traditionally they have focused on the systemic arterial circulation which plays an important role in LV failure, but an uncertain role in RV failure.
Citation
Borovac JA, D'Amario D, Bozic J, Glavas D. Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers. World J Cardiol. 2020 Aug 26;12(8):373-408.Source: https://pubmed.ncbi.nlm.nih.gov/32879702/
Venous Function and Central Venous Pressure: A Physiologic Story
Wonderful and very understandable review of the complex physiology around the venous circulation in normal conditions, and in heart failure. The author has been an expert in this field for many years. It is highly recommended for those wishing to follow the recent advances in targeting the venous circulation to treat heart failure.
